{"entity":{"id":"nct06849492","kind":"trial","name":"HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast Cancer","aka":["SHIFT-001"],"tldr":"A phase 2 trial of camrelizumab, nab-paclitaxel, sacituzumab tirumotecan and lenvatinib in triple-negative breast cancer, run by Fudan University, not yet recruiting.","summary":"HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast Cancer is a phase 2, interventional study registered as NCT06849492 by Fudan University, with a registry enrolment figure of 120 participants, started 2025-04-01 and due to reach its primary completion in 2027-12-31. Interventions recorded: Camrelizumab; Nab-paclitaxel; SKB264; Lenvatinib. Conditions listed: Advanced Triple Negative Breast Cancer. Triple-negative eligibility wording from the registry: \"Histopathologically confirmed recurrent metastatic triple-negative invasive breast cancer (HER2-negative: IHC 0/1+ or IHC 2+ with negative ISH; ER-negative: IHC \\<1%, PR-negative: IHC \\<1%)；\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06849492","url":"https://clinicaltrials.gov/study/NCT06849492"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-metastatic"],"sections":[],"technologies":["adc","checkpoint-inhibitor","cytotoxic-chemotherapy"],"targets":[],"drugs":["camrelizumab","nab-paclitaxel","sacituzumab-tirumotecan","lenvatinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06849492","phase":"2","setting":"An Open, Multicenter Study on the Treatment of Recurrent and Metastatic Triple-negative Breast Cancer Guided by Cell Surface Protein Typing (HIM) in Triple-negative Breast Cancer","sponsor":"Fudan University","enrolled":120,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06849492/","neighbours":{"cancer":[{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"camrelizumab","kind":"drug","name":"Camrelizumab","route":"/drugs/camrelizumab/"},{"id":"lenvatinib","kind":"drug","name":"Lenvatinib","route":"/drugs/lenvatinib/"},{"id":"nab-paclitaxel","kind":"drug","name":"Nab-paclitaxel","route":"/drugs/nab-paclitaxel/"},{"id":"sacituzumab-tirumotecan","kind":"drug","name":"Sacituzumab tirumotecan","route":"/drugs/sacituzumab-tirumotecan/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}